The enhanced binding of nirsevimab to FcRn therefore extends its lifespan, but when bound to RSV, it is not impossible that this binding facilitates entry of the virus into certain cells, particularly in the lower respiratory tract, facilitating or aggravating infection. The gene discussed is FCGRT; the disease is infection.